NORFOLK, Va., December 06, 2025--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the ...
STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo ...
Establishing that a molecule engages with its intended target protein in cells is an essential step in drug discovery and chemical probe development. The term “target engagement” refers to a chemical ...
Kinases constitute a family of more than 500 enzymes and play critical roles in cellular signaling, both in normal and diseased cells. As a result, kinases continue to be key drug targets, especially ...
This poster was originally authored by John Vincent, Matthew Burnham, Gerrit Daubner, and Martin Main of the Medicines Discovery Catapult. It was presented at ELRIG Drug Discovery 2023. Methods to ...
Engagement of intracellular targets is often critical to drug mechanisms. Establishing a target engagement (TE) profile is an important step in small- molecule drug discovery as well as chemical probe ...
- Poster presentation showcases method used to develop a first-of-its-kind assay to assess sabirnetug’s binding to amyloid beta oligomers (AβOs) in Alzheimer’s disease - Company on track to initiate ...
MADISON, Wis.--(BUSINESS WIRE)--A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery.
QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback